ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

MRNA vs ARGX // EV/EBITDA & P/E VALUATION

Moderna Inc. (NASDAQ) VS. argenx SE (NASDAQ) • 15-METRIC TALLY: MRNA 4 — ARGX 7
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (MRNA VS. ARGX) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC MRNA ARGX SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin 55.30% — — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -34.10% 9.90% -44.00 ARGX /roic <GO>
EV/EBITDA & P/E Valuation ACTIVE — 21.0x — TIE /valuation <GO>
Free Cash Flow Yield -2.32% 2.21% -4.53 ARGX /fcf-yield <GO>
Operating Margin -60.00% 13.90% -73.90 ARGX /operating-margins <GO>
Net Profit Margin -60.00% 10.90% -70.90 ARGX /net-margins <GO>
Revenue Growth (YoY) -39.90% 18.70% -58.60 ARGX /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity 15.07 3.74 +11.33 MRNA /balance-sheet <GO>
Piotroski F-Score Quality 5/9 8/9 -3.00 ARGX /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 57.7 51.7 +6.00 MRNA /rsi-technicals <GO>
10Y Yield & FRED Macro Beta 1.10 1.02 +0.08 MRNA /macro-sensitivity <GO>
Forward P/E Multiple 32.0x 27.6x +4.40 ARGX /forward-pe <GO>
Enterprise Scale & Market Cap $88.93B $55.72B $33.21B MRNA /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR MRNA REV ARGX REV MRNA GROSS % ARGX GROSS % MRNA FCF ARGX FCF
FY 2025 $1.94B — 55.3% — -$2.06B —
FY 2024 $3.24B — 54.8% — -$4.05B —
FY 2023 $6.85B — — — -$3.43B —
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
MRNA // BETA 1.10
ARGX // BETA 1.02